A clinical trial involving degarelix has an updated status as of September 24, 2026. The study, titled "Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer" (A-DREAM), is registered under identifier NCT05241860.
This is a Phase 2 trial. Its current status is listed as active, not recruiting, meaning the study is ongoing but is not currently enrolling new participants.
The trial examines interruption of hormonal medications, which may include degarelix, in patients with metastatic prostate cancer who have shown an exceptional response to therapy. No results have been posted for this trial as part of this update. The status change reflects only where the study stands in its process, not any outcome or finding.
Degarelix is an approved compound used in hormonal therapy contexts relevant to this trial. Readers interested in tracking this study further can consult the official trial registration for additional protocol details.
For more background on degarelix, including its approved uses and general profile, see the compound overview.